The opioid crisis, maternal death, and COVID-19 underscore trust as foundational to public health and call for redefinition of what it means to be a US clinician.
AMA J Ethics. 2021;23(3):E265-270. doi:
10.1001/amajethics.2021.265.
Sriya Bhattacharyya, PhD, Aaron S. Breslow, PhD, Jianee Carrasco, and Benjamin Cook, PhD, MPH
Force is codified in law, so force utilization inequity demands that we consider connections between systemic oppression and individuals’ responses in clinical settings.
AMA J Ethics. 2021;23(4):E340-348. doi:
10.1001/amajethics.2021.340.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"